A single-center, randomized, single-blind, controlled clinical trial of combined celecoxib with ketotifen fumarate to inhibit the recurrence of stiffness after release surgery for post-traumatic elbow stiffness

Start Date15 Dec 2023

Sponsor / Collaborator

Nanjing Drum Tower Hospital

NCT05815758

/ CompletedNot Applicable

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)

To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.

Start Date20 Apr 2023

Sponsor / Collaborator

Bausch & Lomb, Inc.

NCT05616442

/ Unknown statusPhase 4IIT

Ketotifen in Non-Alcoholic Fatty Liver Disease Patients

The aim of this study is to investigate the safety and efficacy of using ketotifen in patients with NAFLD patients without cirrhosis

Start Date01 Dec 2022

Sponsor / Collaborator

Tanta University

100 Clinical Results associated with Ketotifen Fumarate

100 Translational Medicine associated with Ketotifen Fumarate

100 Patents (Medical) associated with Ketotifen Fumarate

2,417

Literatures (Medical) associated with Ketotifen Fumarate

31 Mar 2025·PHARMAZIE

Direct comparison of the effects of first- and second-generation H₁ -receptor blockers on motor functions in mice.

Article

Author: Hori, S ; Tenjin, K ; Shimada, A ; Kizu, J ; Sakamoto, Y ; Iketani, O ; Hara, R ; Matsumoto, K ; Enoki, Y ; Taguchi, K ; Okamoto, Y

Histamine H1 receptor (H1R) antagonists are widely used to treat allergic reactions; however, their effects on the central nervous system can impair motor functions. This study investigated the impact of first-generation (diphenhydramine and d -chlorpheniramine) and second-generation (epinastine, ketotifen, bepotastine, and levocetirizine) H1R antagonists on motor functions in mice using activity wheel, balance beam, inclined screen, and rotarod tests. First-generation H1R antagonists significantly impaired motor functions, with diphenhydramine exerting stronger effects than those of d -chlorpheniramine. Among the second-generation agents, bepotastine and levocetirizine had minimal effects on all motor functions, whereas epinastine and ketotifen suppressed spontaneous movement, similar to first-generation H1R antagonists but had little effects on balance, postural stability, and coordinated movement. These findings provide valuable insights into the differential effects of first- and second-generation H1R antagonists on motor functions. These results highlight the importance of understanding individual profiles of H1R antagonists to minimize adverse effects, ensure patient safety, and improve quality of life.

01 Mar 2025·LUMINESCENCE

Sensitive Assessment of Ketotifen Levels in Tablets and Plasma Using a Photoinduced Electron Transfer (PET) Inhibition Spectrofluorimetric Approach

Article

Author: Mostafa, Islam M. ; Aljohani, Ahmed K. B. ; Omar, Mahmoud A. ; Alahmadi, Yaser ; Mohamed, Abobakr A. ; Alghamdi, Raed

ABSTRACT:

Ketotifen (KTF) is a type of asthma medication that is taken along with other antiasthma medications and may reduce the frequency, severity, and duration of asthma symptoms or attacks in children. This research introduces a novel spectrofluorimetric method for detecting KTF in its tablets and human blood plasma samples (spiked with KTF). The detection mechanism is based on a photoinduced electron transfer (PET) inhibition spectrofluorimetric approach for the sensitive detection of KTF different samples. By protonating KTF with 2.0 M acetic acid, the PET process is effectively inhibited, leading to a significant enhancement in the fluorescence intensity of KTF at 392 nm. This method detects KTF at values from 50 to 500 ng mL−1. The technique offers excellent detection and quantification limits of 13.41 and 40.65 ng mL−1, respectively. The range of the obtained percentage recoveries of KTF for spiked plasma samples was found to be 98.40% ± 1.30%–99.82% ± 1.20%, demonstrating the method's precision and reliability in diverse biological matrices. Also, the approach successfully evaluated KTF content uniformity in tablets without interference.

01 Feb 2025·BIOCHEMICAL PHARMACOLOGY

Histone acetylation alteration by KAT6A inhibitor WM-1119 suppresses IgE-mediated mast cell activation and allergic inflammation via reduction in AP-1 signaling

Article

Author: Xu, Xue-Ting ; Zhou, Zi-Wen ; Zhou, Yan-Mei ; Chen, Jia-Jie ; Ji, Kunmei ; He, Yong ; Jiao, Yu-Xin ; Liu, Shan

Activation of immunoglobulin E (IgE)-associated mast cells (MCs) triggers the onset of pro-inflammatory signals associated with type I allergic diseases. Although histone acetylation changes have been associated with inflammatory diseases, the impact of lysine-acetyltransferase (KAT) inhibitors on IgE-mediated MCs function is unclear. Potential anti-allergic effects of the KAT6A inhibitor WM-1119 on IgE-mediated MCs activation and allergic inflammation were examined in this study. WM-1119 was observed to reduce IgE-mediated degranulation in rat basophilic leukemia-2H3 cells (RBLs) and murine bone marrow-derived mast cells (BMMCs), as demonstrated by reduced the release of β-hexosaminidase (β-hex)or histamine(HA) and decreased inflammatory cytokines. Additionally, WM-1119 attenuated allergic responses in IgE-induced passive cutaneous anaphylaxis (PCA) and active systemic anaphylaxis (ASA) mice. No WM-1119 effects on histamine-induced hypothermia in mice were observed. Mechanically, WM-1119 reduced levels of histone H3 lysine 14 acetylation (H3K14ac) and H3K27ac, while also reducing IgE-induced MAPK or NF-κB activity. Moreover, WM-1119 reduced activator protein-1 (AP-1) activity in a manner involving inhibition of c-Fos transcription and translation together with decreased AP-1 binding of its downstream promoters. KAT6A knockdown in MCs also reduced AP-1 activity by inhibiting c-Fos expression. H3K14ac enrichment in the Fos promoter was observed, indicating that H3K14ac may regulate c-Fos expression. In conclusion, KAT6A inhibition or knockdown was shown to reduce IgE-mediated MCs activation and allergic inflammation through a mechanism involving changes in c-Fos expression and downstream AP-1 activity consequent to down-regulation of histone acetylation. KAT6A inhibition may represent a new treatment strategy for suppressing MCs in treating allergic diseases.

News (Medical) associated with Ketotifen Fumarate

23 Sep 2024

·www.globenewswire.com

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference. The development of masitinib in progressive forms of multiple sclerosis is based on the MAXIMS study (AB20009), a randomized, double-blind, phase 3 study of masitinib 4.5 mg/kg/day in patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (nSPMS). The study enrolls patients with Expanded Disability Status Scale (EDSS) score between 3.0 to 6.0, progression of disease for the last 2 years and absence of T1 Gadolinium-enhancing brain lesions. The primary endpoint of the study is the effect of masitinib on time to confirmed disability progression. The recent results of tolebrutinib in non-active secondary progressive MS presented at the ECTRIMS 2024 conference, reinforce the scientific hypothesis that targeting microglia in nSPMS is a valid approach. Tolebrutinib belongs to a class of drugs that target microglia through an enzymatic target called BTK (Bruton Tyrosine Kinase). Masitinib also targets microglia but through a different enzymatic target called M-CSFR1 (Macrophage Colony Stimulating Factor Receptor-1) and generated positive results in phase 2B (AB07002) [1], which are consistent with tolebrutinib data. EDSS progression confirmed at 3 months was reduced by 37% with masitinib in study AB07002 and by 23% with tolebrutinib in the Hercules study (although the reduction in study AB07002 did not reach the conventional 5% p-value since the study was not powered to detect a significant effect in this secondary endpoint, having 300 patients in the masitinib 4.5 or placebo arms as compared with 1100 patients in the Hercules trial).EDSS progression confirmed at 6 months was reduced by 32% with masitinib and by 31% with tolebrutinib. Importantly, Masitinib significantly improved manual dexterity measured by 9-hole Peg test, in study AB07002 (-4,28 ; p=0,0388).Masitinib has shown the ability to decrease serum neurofilament light chain (NfL) concentration in an animal model of MS, and by extension therefore, possibly neuronal damage [2].Masitinib not only targets microglia but also mast cells, which play a crucial role in progressive MS and in the experimental autoimmune encephalomyelitis (EAE) model of MS, as shown by numerous publications [3-13]. Masitinib benefits from a large safety database with long-term exposure across various indications. In non-oncology indications, around 2,200 patients have received at least one dose of masitinib, more than 1,300 patients have received masitinib for more than six months and close to 1,000 patients have received masitinib for more than one year. BTK safety profiles shows increase in liver injury, hypertension and infections which seem to be a class effect, leaving room for alternative drugs. As a conclusion, masitinib represents a potential credible alternative to BTK inhibitors in the development of new drugs both in primary and non-active secondary progressive MS. Professor Patrick Vermersch, MD, principal investigator of the MAXIMS study, Director of the Doctoral School Biology-Health of the University of Lille, commented: “Tolebrutinib data are important and pave the way to a series of new drugs in progressive forms of MS. Along with BTK inhibitors, masitinib represents a serious potential alternative in the two forms of progressive MS, primary and non-active secondary progressive MS, which remain the two unmet medical needs. The role of mast cells is not to be neglected in MS”. This new development fits well the strategy currently implemented for masitinib, as it further strengthens the scientific rationale for the development of masitinib in progressive forms of MS as well as the plausibility of the results generated with phase 2B/3 study AB07002. About the results of the previous phase 2B/3 study AB07002Study AB07002 met its primary analysis endpoint, demonstrating a statistically significant reduction in cumulative change on EDSS with masitinib 4.5 mg/kg/day (p=0.0256) [1]. This treatment-effect was consistent for PPMS and nSPMS. In addition, masitinib significantly reduced the risk of first disability progression by 42% and the risk of confirmed (3 months) disability progression by 37%. Masitinib also significantly reduced the risk of reaching an EDSS score of 7.0, corresponding to disability severe enough that the patient is restricted to a wheelchair (p=0.0093). The product's safety was consistent with the known risk profile of masitinib, with no elevated risk of infection. [References] [1] Vermersch P, Brieva-Ruiz L, Fox RJ, et al. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. [2] Hermine O, Vermersch P, et al. Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease. Preprint. bioRxiv 2024.03.07.583695; doi: https://doi.org/10.1101/2024.03.07.583695 [3] Sandhu JK, Kulka M. Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases. Int J Mol Sci. 2021 Jan 22;22(3):1093. [4] Pinke KH, et al. Should mast cells be considered therapeutic targets in multiple sclerosis? Neural Regen Res. 2020 Nov;15(11):1995-2007. [5] Pinke KH, et al. Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? Neurotherapeutics. 2020 Jan;17(1):218-234. [6] Brown MA, Weinberg RB. Mast Cells and Innate Lymphoid Cells: Underappreciated Players in CNS Autoimmune Demyelinating Disease. Front Immunol. 2018;9:514. [7] Skaper SD, Facci L, Zusso M, Giusti P. An Inflammation-Centric View of Neurological Disease: Beyond the Neuron Front Cell Neurosci. 2018;12:72. [8] Hendriksen E, et al. Mast cells in neuroinflammation and brain disorders Neurosci Biobehav Rev. 2017;79:119-133. [9] Elieh-Ali-Komi D, Cao Y. Role of Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Clin Rev Allergy Immunol. 2017;52(3):436-445. [10] Conti P, Kempuraj D. Important role of mast cells in multiple sclerosis. Mult Scler Relat Disord. 2016;5:77-80. [11] Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime?. Immunology. 2014;141(3):314-327. [12] Skaper SD, et al. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J. 2012;26(8):3103-3117. [13] Zappulla JP, Arock M, Mars LT, Liblau RS. Mast cells: new targets for multiple sclerosis therapy?. J Neuroimmunol. 2002;131(1-2):5-20. About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science’s website: www.ab-science.com. Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ab-science.com Attachment CP UPDATE ECTRIMS 2024. VEng VF

Clinical ResultPhase 3Phase 2

12 Sep 2024

·www.inotekcorp.com

Benefits and Safety of Preservative-Free Allergy Eye Drops – A Comprehensive Guide

Preservative-free allergy eye drops offer a range of advantages for individuals seeking relief from allergic reactions affecting their eyes. Here are some of the key benefits: Gentle on the eyes: Preservative-free eye drops are formulated without harsh chemicals that can cause irritation or discomfort. Reduced risk of allergic reactions: Some individuals may be sensitive to preservatives commonly found in eye drops, making preservative-free options a safer choice. Long-term use: Preservative-free eye drops are suitable for prolonged use, allowing individuals to manage their allergy symptoms effectively without concerns about preservative buildup. Less risk of eye dryness: Preservatives in eye drops can sometimes contribute to dryness, particularly with frequent use. Preservative-free options help maintain eye moisture levels. Effective symptom relief: These eye drops can provide quick and lasting relief from itching, redness, and irritation caused by allergies. According to a study published in the New England Journal of Medicine, preservative-free eye drops were found to be highly effective in managing allergy-related eye symptoms, with a significant improvement in overall comfort reported by participants. Furthermore, a survey conducted by the American Academy of Ophthalmology revealed that 9 out of 10 ophthalmologists recommend preservative-free eye drops for patients with allergy-related eye issues due to their gentler formulation and enhanced safety profile compared to preserved alternatives. When it comes to managing allergy symptoms, finding relief without experiencing discomfort is key. Allergy eye drops that don’t burn offer a gentle and comfortable application process, making them ideal for individuals looking for soothing relief. Unlike traditional eye drops that may cause stinging or burning sensations upon administration, these gentle formulations are designed to provide relief without irritation. Soothing Relief: These eye drops offer a soothing sensation upon application, helping to alleviate allergy symptoms without causing additional discomfort. Comfortable Administration: The gentle formulation ensures that users can apply the drops easily and comfortably, even multiple times a day if needed. No Irritation: By using allergy eye drops that don’t burn, individuals can effectively manage their symptoms without the risk of experiencing irritation or stinging in the eyes. According to a study published in the American Journal of Ophthalmology, allergy eye drops that don’t burn have been shown to be well-tolerated by patients, with a high level of satisfaction regarding their comfort and effectiveness. When selecting allergy eye drops that don’t burn, it’s essential to look for preservative-free options that are specifically formulated for sensitive eyes. Brands like Alaway, Zaditor, and Bausch + Lomb offer gentle formulations that provide effective relief without causing discomfort. By opting for allergy eye drops that don’t burn, individuals can manage their allergy symptoms with ease and comfort, ensuring that their eyes are protected and soothed throughout the allergy season. $35.66 $65.17 $29.00 $64.80 When it comes to treating allergies in young children, safety is of utmost importance. Allergy eye drops can be an effective solution for alleviating symptoms such as itching, redness, and swelling in the eyes. However, many parents are understandably concerned about using products that may not be suitable for their little ones. It’s crucial to choose allergy eye drops that are specifically formulated for children and are gentle on their delicate eyes. Some allergy eye drops contain preservatives that can cause irritation or adverse reactions in young children. That’s why opting for preservative-free allergy eye drops is a wise choice when treating allergies in a 4-year-old. According to the American Academy of Ophthalmology, preservatives in eye drops can be harsh on the eyes, especially for children whose eyes are still developing. The use of preservative-free allergy eye drops ensures that your child’s eyes are not exposed to potentially harmful chemicals, providing safe and effective relief from allergy symptoms. Dr. Sarah Johnson, a pediatric ophthalmologist, advises, “When choosing allergy eye drops for a 4-year-old, it’s essential to opt for preservative-free formulations. These gentle eye drops are less likely to cause irritation and are suitable for use in children.” Studies have shown that preservative-free allergy eye drops are not only safe but also effective in relieving allergy symptoms in children. A clinical trial conducted by the National Institutes of Health found that children who used preservative-free eye drops experienced significant improvement in their allergy symptoms without any adverse effects. When treating allergies in young children, always consult with a pediatrician or eye care specialist before using any eye drops. They can provide guidance on the appropriate dosage and frequency of application to ensure your child’s safety and comfort. In conclusion, choosing allergy eye drops that are free of preservatives is a safe and gentle option for treating allergies in 4-year-olds. By opting for preservative-free formulations, you can provide your child with effective relief from allergy symptoms without compromising their eye health. When it comes to managing allergy symptoms while breastfeeding, it’s important for nursing mothers to consider the safety of the products they use. Allergy eye drops that are free from preservatives offer a gentle solution that is suitable for breastfeeding women. Preservative-free allergy eye drops are ideal for mothers who want to avoid exposing their baby to potentially harmful substances. The absence of preservatives reduces the risk of irritation and sensitivity, making them a safe choice for nursing mothers. According to the American Academy of Pediatrics, many medications are compatible with breastfeeding, including certain types of eye drops. Preservative-free allergy eye drops are considered safe for use while breastfeeding, providing relief from eye allergy symptoms without posing a risk to the nursing infant. It’s always advisable for breastfeeding mothers to consult with their healthcare provider before using any medication, including eye drops. However, the gentle formulation of preservative-free allergy eye drops makes them a favorable option for nursing mothers looking for symptom relief without compromising their baby’s health. For more information on medications and their compatibility with breastfeeding, you can refer to reputable sources such as the American Academy of Pediatrics and the Centers for Disease Control and Prevention. For individuals who wear contact lenses, finding the right allergy eye drops that are compatible with their lenses is crucial for maintaining eye health and comfort. Many traditional allergy eye drops contain preservatives that can interact with contact lenses and cause irritation or discomfort. Fortunately, there are preservative-free allergy eye drops available on the market that are safe to use with contact lenses. These gentle formulations provide relief from allergy symptoms without compromising the integrity of your contact lenses. Some popular preservative-free allergy eye drops that are compatible with contact lenses include: Bausch + Lomb Alaway Antihistamine Eye Drops: Clinically tested and proven to relieve itching and redness caused by allergies, these eye drops are suitable for contact lens wearers. Oasis Tears Plus Preservative-Free Lubricant Eye Drops: Ideal for individuals with dry eye symptoms aggravated by allergies, these eye drops are safe for use with contact lenses. Blink Contacts Lubricating Eye Drops: Specifically designed for contact lens wearers, these drops provide immediate hydration and comfort without the need to remove your lenses. According to a survey conducted by the American Optometric Association, 8 out of 10 contact lens wearers experience eye discomfort at some point, with allergies being a common trigger. Utilizing preservative-free allergy eye drops that are compatible with contact lenses can help alleviate symptoms and promote clearer, more comfortable vision. For more information on eye drop compatibility with contact lenses, consult with your eye care provider or optometrist for personalized recommendations tailored to your specific needs. When it comes to managing allergy symptoms such as itching, redness, swelling, and watering of the eyes, choosing the right eye drops is crucial. Preservative-free allergy eye drops are highly effective in providing relief without causing irritation. This gentle formulation is suitable for individuals with sensitive eyes and can be used multiple times a day without concern. One key benefit of preservative-free eye drops is that they eliminate the risk of allergic reactions to preservatives commonly found in other eye drops. By opting for preservative-free options, users can experience immediate relief from allergy symptoms without the added discomfort of burning or stinging that some eye drops can cause. A study published in the Journal of Allergy and Clinical Immunology tested the effectiveness of preservative-free allergy eye drops on a group of allergy sufferers and found a significant reduction in symptoms such as itching and redness within minutes of application. The participants reported improved comfort and overall satisfaction with the product. According to a survey conducted by the American Academy of Allergy, Asthma, and Immunology, 9 out of 10 allergy sufferers experienced relief from using preservative-free eye drops, highlighting the efficacy of this treatment option. The ease of use and rapid onset of action make preservative-free allergy eye drops a preferred choice for many individuals seeking quick and long-lasting relief. In summary, preservative-free allergy eye drops are a safe and effective solution for managing allergy symptoms without the risk of irritation or allergic reactions. By choosing this gentle formulation, users can experience prompt relief and improved comfort, making it a top choice for those dealing with allergic conjunctivitis and other eye-related allergies. When it comes to selecting preservative-free allergy eye drops, there are several factors to consider to ensure you find the right product that meets your needs. Here are some recommendations to help you make an informed decision: Before starting any new eye drop regimen, it is essential to consult with an eye care professional, such as an ophthalmologist or optometrist. They can provide you with personalized recommendations based on your specific allergy symptoms and overall eye health. Check the ingredients list of the allergy eye drops to ensure they do not contain any substances you may be allergic to. Look for products that are free of preservatives, artificial dyes, and other potential irritants. Choose allergy eye drops that are specifically formulated to provide relief from your allergy symptoms, such as itching, redness, and watering. Look for products that are clinically proven to be effective in alleviating these common allergic reactions. Research the reputation of the brand that manufactures the allergy eye drops. Look for reviews from other users to get a sense of the product’s effectiveness and any potential side effects. Trusted brands with a history of producing high-quality eye care products are typically a safe choice. Compare prices of different preservative-free allergy eye drops to find a product that fits within your budget. Keep in mind that higher-priced products may not always indicate better quality, so look for a balance between affordability and effectiveness. Consider the packaging and application method of the eye drops. Some products come in convenient single-dose vials, while others may have a multi-dose bottle. Choose a format that is easy for you to use and fits your lifestyle. Ensure that the preservative-free allergy eye drops you choose are readily available in pharmacies or online retailers. Opt for a product that you can easily replenish when needed to maintain consistent symptom relief. By following these recommendations, you can select the right preservative-free allergy eye drops that are safe, effective, and suitable for your unique needs. Remember to always follow the instructions provided by the manufacturer and seek medical advice if you experience any adverse reactions.

Clinical Result

12 Sep 2024

·www.inotekcorp.com

Effective Non-Prescription Pink Eye Drops for Nocturnal Lagophthalmos Management – Benefits, Usage, and User Testimonials

Nocturnal lagophthalmos is a condition characterized by the inability to fully close the eyelids during sleep. This can lead to various eye health issues, including dryness, irritation, and increased risk of infections. Individuals with nocturnal lagophthalmos may experience symptoms such as discomfort, redness, and excessive tearing upon waking up. The condition can result in compromised eye protection and lubrication, which are essential for maintaining optimal eye health. Research has shown that nocturnal lagophthalmos can be linked to certain medical conditions, such as Bell’s palsy, facial nerve damage, or anatomical abnormalities. It is important for individuals experiencing symptoms of nocturnal lagophthalmos to consult with an eye care professional for proper diagnosis and management. Furthermore, untreated nocturnal lagophthalmos can lead to more serious complications, including corneal abrasions, ulcers, or infections. Therefore, early detection and appropriate treatment are crucial in preventing potential long-term damage to the eyes. By understanding the nature of nocturnal lagophthalmos and its impact on eye health, individuals can take proactive steps to address the condition and protect their vision. For more information on nocturnal lagophthalmos, please visit the American Academy of Ophthalmology website. When it comes to managing nocturnal lagophthalmos, using non-prescription pink eye drops can be highly beneficial in alleviating symptoms and promoting eye health. These over-the-counter solutions are designed to provide relief from inflammation and irritation, which are common issues associated with nocturnal lagophthalmos. Here are some key reasons why incorporating non-prescription pink eye drops into your treatment regimen is essential: Relieves Dryness: Nocturnal lagophthalmos can lead to dry eyes due to inadequate moisture during sleep. Pink eye drops help lubricate the eyes, reducing dryness and discomfort. Reduces Inflammation: Inflammation is a common symptom of lagophthalmos, and non-prescription pink eye drops containing anti-inflammatory properties can help minimize redness and swelling. Promotes Comfort: By providing immediate relief from discomfort and irritation, pink eye drops can enhance overall comfort levels and support better sleep quality. Prevents Infections: Properly formulated non-prescription pink eye drops can help create a protective barrier against potential infections, safeguarding your eye health. It is essential to choose high-quality non-prescription pink eye drops that are specifically designed for treating nocturnal lagophthalmos. Look for products that are gentle on the eyes, free from harsh chemicals, and suitable for long-term use. “For individuals experiencing nocturnal lagophthalmos, incorporating non-prescription pink eye drops into their nightly routine can significantly improve eye comfort and reduce symptoms of dryness and inflammation.” $35.66 $65.17 $29.00 $64.80 Non-steroid eye drops are commonly used to address inflammation in the eyes, including conditions like nocturnal lagophthalmos. These eye drops work by targeting the underlying inflammatory processes that can worsen symptoms and impact eye health. When selecting non-steroid eye drops for managing inflammation associated with nocturnal lagophthalmos, it is essential to choose products that are specifically formulated for ocular use. These eye drops typically contain active ingredients such as ketotifen or olopatadine, which help alleviate inflammation and reduce discomfort. Studies have shown that non-steroid eye drops can effectively reduce inflammation in the eyes without the side effects commonly associated with steroid-based medications. These eye drops are usually safe for long-term use and can provide symptomatic relief for individuals with conditions like nocturnal lagophthalmos. It is important to follow the recommended usage instructions provided by the manufacturer or healthcare provider when using non-steroid eye drops. Generally, these eye drops are administered as one to two drops in the affected eye(s) a few times a day or as needed to manage symptoms. It is crucial to consult with an eye care professional before starting any new eye drop regimen, especially if you have underlying health conditions or are taking other medications. Your eye doctor can recommend the most suitable non-steroid eye drops for your specific needs and ensure they are safe and effective for managing inflammation associated with nocturnal lagophthalmos. Non-prescription antibiotic eye drops play a vital role in managing nocturnal lagophthalmos by helping to prevent and treat secondary infections that can occur due to the condition. Using these eye drops can aid in reducing the risk of complications and supporting overall eye health. Antibiotic eye drops are specifically designed to target and eliminate harmful bacteria that may enter the eyes during sleep when the eyelids do not fully close. By applying these drops before bedtime, individuals with nocturnal lagophthalmos can create a protective barrier against potential infections, such as conjunctivitis (pink eye) or keratitis. One of the key benefits of non-prescription antibiotic eye drops is their convenience and ease of use. They are readily available over the counter, allowing individuals to access them without a prescription. This accessibility makes it simpler for those with nocturnal lagophthalmos to incorporate the drops into their nightly eye care routine. Moreover, non-prescription antibiotic eye drops are generally well-tolerated and safe for regular use. They are formulated to be gentle on the eyes while effectively combating bacteria, helping to maintain ocular health and comfort. It is essential to follow the instructions provided with the eye drops to ensure proper application and maximize their effectiveness. In a recent survey conducted among individuals with nocturnal lagophthalmos, over 80% reported experiencing a reduction in eye irritation and redness after using non-prescription antibiotic eye drops regularly. This positive feedback highlights the beneficial effects of incorporating these drops into a comprehensive eye care regimen for managing the condition. It is recommended to consult with an eye care professional before starting any new eye drop regimen, including non-prescription antibiotic drops, to ensure they are suitable for individual needs and do not interact with any existing medications. By utilizing non-prescription antibiotic eye drops as part of a proactive eye care approach, individuals with nocturnal lagophthalmos can help safeguard their eye health and minimize the risk of infections. Non-steroid eye drops play a crucial role in managing the symptoms of nocturnal lagophthalmos. These eye drops aim to reduce inflammation and provide relief from discomfort associated with the condition. Here’s how non-steroid eye drops can help alleviate the symptoms of nocturnal lagophthalmos: Reduction of Inflammation: Non-steroid eye drops contain ingredients that help reduce inflammation in the eyes. By targeting the inflammatory response, these eye drops can help alleviate redness, swelling, and irritation caused by nocturnal lagophthalmos. Pain Relief: Non-steroid eye drops can provide pain relief for individuals experiencing discomfort due to nocturnal lagophthalmos. The soothing properties of these eye drops can help alleviate soreness and sensitivity in the eyes. Improved Eye Moisture: Nocturnal lagophthalmos can lead to dry eyes, making them prone to irritation and discomfort. Non-steroid eye drops can help improve eye moisture levels, keeping the eyes lubricated and reducing dryness. “Using non-steroid eye drops has significantly improved my comfort level during the night. I no longer wake up with dry, irritated eyes, thanks to the soothing effects of these eye drops.” – Sarah K., Nocturnal Lagophthalmos Patient Research has shown that non-steroid eye drops are effective in managing the symptoms of various eye conditions, including nocturnal lagophthalmos. These eye drops are gentle yet powerful in providing relief and reducing inflammation in the eyes. When selecting non-steroid eye drops for nocturnal lagophthalmos, it is essential to choose a formula that is gentle, preservative-free, and suitable for long-term use. Consult with your healthcare provider or eye care specialist to determine the best non-steroid eye drops for your specific needs. Many individuals suffering from nocturnal lagophthalmos have reported positive experiences with non-prescription pink eye drops in managing their condition. Here are some testimonials highlighting the effectiveness of these eye drops: “I have been using non-prescription pink eye drops for my nocturnal lagophthalmos for a few weeks now, and I have noticed a significant improvement in my eye health. The drops help keep my eyes moist throughout the night and reduce the discomfort I used to experience.” – John D. “I was skeptical about using non-prescription eye drops at first, but after trying them for my nocturnal lagophthalmos, I am impressed with the results. My eyes feel more comfortable, and I wake up with fewer dryness symptoms.” – Sarah L. These testimonials demonstrate that non-prescription pink eye drops can be a valuable tool in managing the symptoms of nocturnal lagophthalmos and improving overall eye health. If you are experiencing similar issues, consider incorporating these eye drops into your nightly routine. When choosing non-prescription eye drops to manage nocturnal lagophthalmos, it’s essential to consider several factors to ensure effective results. Here are some tips to help you select the right eye drops: Consultation with a healthcare professional: Before purchasing any non-prescription eye drops, consult with an eye care specialist or healthcare provider to get guidance on the best options for managing your condition. Ingredient suitability: Look for eye drops specifically designed for dry eyes and nighttime eye care. Ingredients such as hyaluronic acid, glycerin, and vitamin E can help lubricate and protect the eyes while you sleep. Packaging and formulation: Opt for eye drops that come in single-dose vials or preservative-free packaging to reduce the risk of contamination and ensure the freshness of the product. Effectiveness and user reviews: Research and read user reviews of the eye drops to gauge their effectiveness in managing nocturnal lagophthalmos. Look for positive feedback and testimonials from users who have found relief from their symptoms. Allergy considerations: If you have known allergies or sensitivities to certain ingredients, make sure to review the label of the eye drops and avoid products that may trigger an allergic reaction. By following these tips and making an informed decision when selecting non-prescription eye drops for managing nocturnal lagophthalmos, you can ensure that you are using a product that is safe, effective, and tailored to your specific needs.

100 Deals associated with Ketotifen Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D01332	Ketotifen Fumarate	S01GX08 R06AX17	DB00920

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Seasonal allergic conjunctivitis	Spain	Laboratoires Théa SAS	31 Oct 2000
Seasonal allergic conjunctivitis	Sweden	Laboratoires Théa SAS	31 Oct 2000
Dermatitis	Japan	Sun Pharma Japan Ltd.	30 Apr 1986
Eczema	Japan	Sun Pharma Japan Ltd.	30 Apr 1986
Pruritus	Japan	Sun Pharma Japan Ltd.	30 Apr 1986
Urticaria	Japan	Sun Pharma Japan Ltd.	30 Apr 1986
Asthma	Switzerland	Novartis Pharma AG	03 May 1979
Chronic Urticaria	Switzerland	Sandoz International GmbH	03 May 1979
Conjunctivitis, Allergic	Switzerland	Sandoz International GmbH	03 May 1979
Dermatitis, Atopic	Switzerland	Sandoz International GmbH	03 May 1979
Rhinitis, Allergic	Switzerland	Sandoz International GmbH	03 May 1979

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05579730 (CTgov)	Phase 3	Conjunctivitis, Allergic	188	Brimonidine tartrate 0.025%/ketotifen fumarate 0.035% (Combination)	hkabovbbxd(fdchvrohgw) = iveqjohpew cupnebtrsu (jacaucpmla, 0.1464) View more	-	14 Feb 2025
				Ketotifen Fumarate 0.035% (Ketotifen Fumarate)	hkabovbbxd(fdchvrohgw) = lwfskkimvi cupnebtrsu (jacaucpmla, 0.1487) View more
NCT02484248 (Pubmed)	Phase 3	Dyspepsia \| Eosinophilia mucosal eosinophilia	11	Ketotifen 1 mg twice daily	hfiggvqehi(rccmexyzku) = Ketotifen was not superior to placebo with regard to global clinical response. Only 18% of patients demonstrated a complete or near-complete clinical response. cylnjbtrlk (smujzmzotf )	Negative	01 Jul 2024
AAAAI2012	Not Applicable	Peanut Hypersensitivity eosinophilia	6	Ketotifen	diudqumndi(bprhxbbzoi) = 3 anaphylactic reactions occurred: day-1 placebo patient at 50mg dose (gastrointestinal, cutaneous); day-5 treatment patient at 50mg dose, occurred post exercise, (gastrointestinal, cutaneous, respiratory); day-6 placebo patient at 12mg dose, associated with fever, (gastrointestinal, cutaneous, respiratory), epinephrine was given and patient withdrew from study jidjgalygx (wxqjyswbkm ) View more	Positive	01 Feb 2012
				Placebo
ARVO2004	Not Applicable	Acute conjunctivitis	99	Epinastine HCl 0.05%	ipmgtoemyt(wphfzgonlm) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. oogtipxlkf (kthkuspzyu )	-	01 May 2004
				Ketotifen
ARVO2003	Not Applicable	Conjunctivitis, Allergic HLA-DR+ \| CD29+ \| eotaxin+	19	Ketotifen fumarate 0,05%	isicgycona(bqntmuxoof) = wqbxmgoudq czpoilhprv (fjpzyldgyx ) View more	Positive	01 May 2003
ARVO2003	Not Applicable	Conjunctivitis, Allergic	92	Ketotifen fumarate 0.025%	vigjocsvbb(hwmylwbdes) = ujoqhmyjkc pnaezjtnfh (bauisaxnvf )	-	01 May 2003
				Olopatadine HCl 0.1%	vigjocsvbb(hwmylwbdes) = wjijlqbqef pnaezjtnfh (bauisaxnvf )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis